Compare · ALEC vs GILD
ALEC vs GILD
Side-by-side comparison of Alector Inc. (ALEC) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALEC and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.36B, about 883.4x ALEC ($181.5M).
- Over the past year, ALEC is up 12.5% and GILD is up 13.4% - GILD leads by 0.9 points.
- GILD has been more active in the news (19 items in the past 4 weeks vs 4 for ALEC).
- Both have 25 recent analyst ratings on file.
- Company
- Alector Inc.
- Gilead Sciences Inc.
- Price
- $1.62-0.61%
- $128.17-0.64%
- Market cap
- $181.5M
- $160.36B
- 1M return
- -33.61%
- -4.49%
- 1Y return
- +12.50%
- +13.44%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 1992
- News (4w)
- 4
- 19
- Recent ratings
- 25
- 25
Alector Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ALEC
- Director Scheller Richard H was granted 10,833 shares, increasing direct ownership by 11% to 106,199 units (SEC Form 4)
- Chief Executive Officer Rosenthal Arnon sold $172,191 worth of shares (87,216 units at $1.97), decreasing direct ownership by 4% to 2,367,206 units (SEC Form 4) to cover withholding tax
- Principal Accounting Officer Wong-Sarad Grace sold $17,813 worth of shares (9,184 units at $1.94) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,461 units (SEC Form 4) to satisfy tax liability
- CFO & Chief Business Officer Berkley Neil Lindsay sold $38,221 worth of shares (19,360 units at $1.97), decreasing direct ownership by 5% to 379,900 units (SEC Form 4) to cover taxes
- Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.
- SEC Form 8-K filed by Alector Inc.
- SEC Form 424B5 filed by Alector Inc.
- SEC Form 10-Q filed by Alector Inc.
- Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Latest GILD
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology